LSTA — Lisata Therapeutics Share News
0.000.00%
Last trade - 00:00- $30.60m
- $17.28m
- $0.17m
Brief: Caladrius Biosciences And Cend Therapeutics Announce Publication Of Pancreatic Cancer Trial Data In The Lancet Gastroenterology And Hepatology
Brief: Caladrius Biosciences Says Cend Therapeutics Treated First Patient In Phase 2B Trial Of Cend-1
Brief: Caladrius Biosciences Provides Update On Phase 2B Freedom Trial Of Xowna® In Coronary Microvascular Dysfunction
NASDAQ TRADE HALT HALT NEWS PENDING AT 04:17 PM
Brief: Caladrius Biosciences Announces Idmc Recommendation To Advance Clbs201 Trial For Treatment Of Diabetic Kidney Disease
Brief: Caladrius Biosciences Reports First Quarter 2022 Financial Results
Caladrius Biosciences Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Caladrius Biosciences, Cend Therapeutics Report Definitive Merger Agreement
NASDAQ RESUMED AT 07:30 AM
Brief: Caladrius Biosciences And CEND Therapeutics Announce Definitive Merger Agreement
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Caladrius Biosciences gains on starting kidney disease therapy trial
Brief: Caladrius Biosciences Treats First Patient In Trial Of CLBS201 For Treatment Of Diabetic Kidney Disease
Motor racing-Hulkenberg to step in again for Vettel at Saudi Arabian GP (updated)
U.S. RESEARCH ROUNDUP- Adobe, Aligos Therapeutics
Caladrius Biosciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Caladrius Biosciences Reports Fourth Quarter And Full Year 2021 Results
Caladrius Biosciences Inc expected to post a loss of 14cents a share - Earnings Preview
Caladrius Biosciences Inc expected to post a loss of 14 cents a share - Earnings Preview